KR890011599A - 향정신성 활성이 있는 화합물, 이를 함유하는 약제 및 중추신경계 장애를 치료 및 예방하기위한 이의 용도 - Google Patents
향정신성 활성이 있는 화합물, 이를 함유하는 약제 및 중추신경계 장애를 치료 및 예방하기위한 이의 용도 Download PDFInfo
- Publication number
- KR890011599A KR890011599A KR1019890000861A KR890000861A KR890011599A KR 890011599 A KR890011599 A KR 890011599A KR 1019890000861 A KR1019890000861 A KR 1019890000861A KR 890000861 A KR890000861 A KR 890000861A KR 890011599 A KR890011599 A KR 890011599A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- carbon atoms
- optionally substituted
- radical
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 36
- 239000003814 drug Substances 0.000 title claims 5
- 230000000694 effects Effects 0.000 title claims 3
- 208000015114 central nervous system disease Diseases 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 64
- -1 Aliphatic radicals Chemical class 0.000 claims 51
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 22
- 150000002431 hydrogen Chemical group 0.000 claims 19
- 150000003254 radicals Chemical class 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 239000011593 sulfur Substances 0.000 claims 5
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims 4
- 239000005541 ACE inhibitor Substances 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 4
- 235000008206 alpha-amino acids Nutrition 0.000 claims 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006709 (C5-C7) cycloalkenyl group Chemical group 0.000 claims 1
- ADKDJHASTPQGEO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrole Chemical compound C1CNC2CCCC21 ADKDJHASTPQGEO-UHFFFAOYSA-N 0.000 claims 1
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 claims 1
- PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 claims 1
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical compound C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 claims 1
- MFOUWLGLIHXCOZ-UHFFFAOYSA-N 2,3,3a,4,5,7a-hexahydro-1h-indole Chemical compound C1CC=CC2NCCC21 MFOUWLGLIHXCOZ-UHFFFAOYSA-N 0.000 claims 1
- NINJAJLCZUYDGV-UHFFFAOYSA-N 2-azaspiro[4.4]nonane Chemical compound C1CCCC21CNCC2 NINJAJLCZUYDGV-UHFFFAOYSA-N 0.000 claims 1
- SFCOKGCNIPSUQF-UHFFFAOYSA-N 2-azaspiro[4.5]decane Chemical compound C1NCCC21CCCCC2 SFCOKGCNIPSUQF-UHFFFAOYSA-N 0.000 claims 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 230000000049 anti-anxiety effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 150000005840 aryl radicals Chemical class 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 claims 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000005633 phthalidyl group Chemical group 0.000 claims 1
- 239000004089 psychotropic agent Substances 0.000 claims 1
- 230000000506 psychotropic effect Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE?P3802303.2? | 1988-01-27 | ||
| DE3802303 | 1988-01-27 | ||
| DE3802760 | 1988-01-30 | ||
| DE?P3802760.7? | 1988-01-30 | ||
| DE3813819 | 1988-04-22 | ||
| DE?P3813819.0? | 1988-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR890011599A true KR890011599A (ko) | 1989-08-21 |
Family
ID=27197111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019890000861A KR890011599A (ko) | 1988-01-27 | 1989-01-27 | 향정신성 활성이 있는 화합물, 이를 함유하는 약제 및 중추신경계 장애를 치료 및 예방하기위한 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4999370A (fr) |
| EP (1) | EP0331609A3 (fr) |
| JP (1) | JPH01246222A (fr) |
| KR (1) | KR890011599A (fr) |
| CN (1) | CN1038096A (fr) |
| AU (1) | AU615252B2 (fr) |
| DK (1) | DK33989A (fr) |
| FI (1) | FI890370A (fr) |
| IL (1) | IL89082A0 (fr) |
| MA (1) | MA21480A1 (fr) |
| NO (1) | NO890330L (fr) |
| TN (1) | TNSN89009A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA927211B (en) * | 1991-09-27 | 1993-03-24 | Merrell Dow Pharma | Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE. |
| US5455242A (en) * | 1991-09-27 | 1995-10-03 | Merrell Dow Pharmaceuticals Inc. | Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace |
| US5491241A (en) * | 1993-10-18 | 1996-02-13 | Eli Lilly And Company | Bicyclic intermediates for excitatory amino acid receptor antagonists |
| US5530013A (en) * | 1994-02-14 | 1996-06-25 | American Home Products Corporation | Venlafaxine in the inducement of cognition enhancement |
| CN1047384C (zh) * | 1994-07-28 | 1999-12-15 | 北京大学 | 雷米普利的合成方法 |
| US6610497B1 (en) * | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| US6812355B2 (en) | 2002-10-22 | 2004-11-02 | Sekhsaria Chemicals Limited | Process for the manufacture of citalopram hydrobromide from 5-bromophthalide |
| EP2537534B1 (fr) | 2011-06-22 | 2014-12-17 | Hexal AG | Esters d'acide (1S,9S)-9-[[(1S)-1-carboxy-3-phénylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazépine-1-carboxylique et leur utilisation thérapeutique |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3151690A1 (de) * | 1981-12-29 | 1983-07-07 | Hoechst Ag, 6230 Frankfurt | "neue derivate bicyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung" |
| DE3333454A1 (de) * | 1983-09-16 | 1985-04-11 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern |
| DE3333455A1 (de) * | 1983-09-16 | 1985-04-11 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung n-alkylierter dipeptide und deren estern |
| DE3431541A1 (de) * | 1984-08-28 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | Cis,endo-2-azabicycloalkan-3-carbonsaeure-derivate, verfahren zu deren herstellung, deren verwendung sowie zwischenprodukte bei deren herstellung |
| DE3610391A1 (de) * | 1986-03-27 | 1987-10-08 | Hoechst Ag | Verbindungen mit nootroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe cognitiver dysfunktionen |
| DE3639879A1 (de) * | 1986-11-21 | 1988-06-01 | Hoechst Ag | Verfahren zur herstellung von mono-, bi- und tricyclischen aminosaeuren, zwischenprodukte dieses verfahrens sowie ein verfahren zu deren herstellung |
| DE3641451A1 (de) * | 1986-12-04 | 1988-06-16 | Hoechst Ag | Derivate bicyclischer aminocarbonsaeuren, verfahren und zwischenprodukte zu deren herstellung sowie deren verwendung |
| IL88502A (en) * | 1987-12-14 | 1993-04-04 | Squibb & Sons Inc | Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor |
-
1989
- 1989-01-18 EP EP19890710005 patent/EP0331609A3/fr not_active Withdrawn
- 1989-01-24 MA MA21722A patent/MA21480A1/fr unknown
- 1989-01-25 FI FI890370A patent/FI890370A/fi not_active Application Discontinuation
- 1989-01-25 US US07/301,297 patent/US4999370A/en not_active Expired - Fee Related
- 1989-01-26 IL IL89082A patent/IL89082A0/xx unknown
- 1989-01-26 NO NO89890330A patent/NO890330L/no unknown
- 1989-01-26 JP JP8915203A patent/JPH01246222A/ja active Pending
- 1989-01-26 AU AU28844/89A patent/AU615252B2/en not_active Ceased
- 1989-01-26 DK DK033989A patent/DK33989A/da not_active Application Discontinuation
- 1989-01-27 TN TNTNSN89009A patent/TNSN89009A1/fr unknown
- 1989-01-27 KR KR1019890000861A patent/KR890011599A/ko not_active Application Discontinuation
- 1989-01-27 CN CN89100465A patent/CN1038096A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL89082A0 (en) | 1989-08-15 |
| AU2884489A (en) | 1989-07-27 |
| DK33989D0 (da) | 1989-01-26 |
| EP0331609A3 (fr) | 1992-07-01 |
| AU615252B2 (en) | 1991-09-26 |
| CN1038096A (zh) | 1989-12-20 |
| FI890370A0 (fi) | 1989-01-25 |
| FI890370A (fi) | 1989-07-28 |
| MA21480A1 (fr) | 1989-10-01 |
| EP0331609A2 (fr) | 1989-09-06 |
| DK33989A (da) | 1989-07-28 |
| NO890330D0 (no) | 1989-01-26 |
| US4999370A (en) | 1991-03-12 |
| JPH01246222A (ja) | 1989-10-02 |
| NO890330L (no) | 1989-07-28 |
| TNSN89009A1 (fr) | 1991-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5098910A (en) | Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs | |
| US5256687A (en) | Pharmaceutical composition for the treatment of high blood pressure | |
| KR840009076A (ko) | N-알킬화 디펩티드의 제조방법 | |
| KR830007519A (ko) | 카복시알킬 디펩타이드의 제조방법 | |
| CA1320904C (fr) | Methode de traitement de l'atherosclerose, de la thrombose et des maladies des vaisseaux peripheriques | |
| KR890011599A (ko) | 향정신성 활성이 있는 화합물, 이를 함유하는 약제 및 중추신경계 장애를 치료 및 예방하기위한 이의 용도 | |
| US5091427A (en) | Piperazinediones having a psychotropic action | |
| US5744496A (en) | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors | |
| CA1332350C (fr) | Combinaison d'inhibiteurs de l'enzyme de conversion de l'angiotensine avec des modulateurs des canaux potassiques et leur utilisation dans des composes pharmaceutiques | |
| KR890011905A (ko) | 아미노산 글리세라이드, 이들의 제조방법, 이들을 함유하는 약제 및 이들의 용도 | |
| US5684016A (en) | Method of treating cardiac insufficiency | |
| KR910004189A (ko) | 심장 및 혈관의 비대 및 과형성을 치료하는 방법 | |
| KR870008841A (ko) | 앤지오텐신 전환효소 억제성 화합물의 제조방법 | |
| US5231080A (en) | Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease | |
| US5231084A (en) | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons | |
| KR890013057A (ko) | 향정신적으로 작용하는 아미노산 아미드, 이의 제조방법, 이를 함유하는 성분 및 이의 용도 | |
| EP0114067B1 (fr) | Compositions pour le traitement d'hypertension | |
| KR940010032B1 (ko) | 고혈압 치료용 약제학적 조성물의 제조방법 | |
| KR920009392A (ko) | 단백뇨증을 치료하기 위한, 안지오텐신 전환효소 억제제와 칼슘 길항제와의 혼합물의 용도 | |
| KR890005145A (ko) | 아미노산 에스테르 이들의 제조방법 이들을 함유하는 약제 및 이들의 용도 | |
| JPS60209527A (ja) | 緑内障の治療法 | |
| US3720768A (en) | Aspergillic acid as an antihypertensive agent | |
| KR890002025A (ko) | 인식 보조 작용을 갖는 화합물, 이들을 함유하는 약제, 및 인식 기능장애를 치료하고 예방하는데 있어서의 이들의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |